Reactivation of peritoneal and pleural tuberculosis during hepatitis C treatment with direct-acting antivirals

Pedrosa, Marc; Nogales, Sara; Vergara, Mercedes; Miquel, Mireia; Casas, Meritxell; Dalmau, Blai; Font, Bernat; Sánchez-Delgado, Jordi

doi:10.1016/j.gastre.2019.02.019

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hepatitis B or hepatitis C co-infection with tuberculosis increase the risk of treatment failure [19] activates latent tuberculosis [20][21][22], increase the risk of mortality [23], and drug-induced liver injury [24][25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study

Feleke

Adane

et al. 2020

Virol J

View full text Add to dashboard Cite

Background This study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis. Methods Prospective cohort study design was implemented. The data were collected from September 2016 – May 2019. Systematic random sampling was used to select the study participants. Baseline data were collected before the patient starts DOTS, the sign of liver toxicity was assessed every week. Tuberculosis treatment outcomes and WHO clinical stage was recorded at the end of 6th months. Descriptive statistics were used to estimate the prevalence of hepatitis B, hepatitis C viral infections and their effect on tuberculosis treatment outcomes. Binary logistic regression was used to identify the determinants of hepatitis B and C infections. The Kaplan Meier survival curve was used to estimate the survival of tuberculosis patient and Cox regression was used to identify the predictors of drug-induced hepatitis. Results A total of 3537 tuberculosis patients were followed. The prevalence of hepatitis B and C viral infection among tuberculosis patients were 15.1 and 17.3% respectively. Hepatitis B viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. Hepatitis C viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. The incidence density for liver toxicity among tuberculosis patients was 843/15707 person-months and liver toxicity was determined by HIV, Hepatitis B, Hepatitis C, the severity of tuberculosis and chronic illnesses. Conclusion Decision-makers should consider incorporating screening for hepatitis B and C viral infection during tuberculosis treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study

Feleke

Adane

et al. 2020

Virol J

View full text Add to dashboard Cite

show abstract

“…Coinfection with HBV in people with TB increases the risk of treatment failure, 24 can reactivate latent TB, 25 , 26 and induce drug-related liver injury. 27 , 28 , 29 Some authors have recommended that HBV screening in people with TB could improve its management due to the possibility of coexistence with HBV in endemic areas.…”

Section: Discussionmentioning

confidence: 99%

Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study

Ghezeldasht

Soleimanpour

Hedayati-Moghaddam

et al. 2023

Journal of Virus Eradication

View full text Add to dashboard Cite

“…Потенциальной проблемой наличия вирусного гепатита В или С у пациента с туберкулезом является более высокий риск резистентности к терапии, а также ее переносимости, ассоциации с повреждением печени и активацией латентного туберкулеза [9][10][11][12]. Также «дуэт» этих заболеваний может создавать значительные трудности в лечении гепатита [2].…”

unclassified

The role of viral hepatitis B and C in the development of adverse outcomes in patients after tuberculosis

Oskin

Filippov

2023

jour

View full text Add to dashboard Cite

Despite the study of the epidemiology of tuberculosis and its co-infection over the past decades, a number of questions remain, including those related to the impact of co-infection on survival depending on the chosen tuberculosis treatment regimen, the likelihood of adverse outcomes in the form of gastrointestinal bleeding and cirrhosis of the liver and their relationship with the therapy of the underlying disease. The purpose of the study: to evaluate the survival of patients with tuberculosis who have co-infection (viral hepatitis B and C) and receive multicomponent chemotherapy. Materials and Methods: The study included all patients who received treatment for active tuberculosis and had viral hepatitis B and/or C from 01/01/2004 to 12/31/2020. A total of 1687 patients were included. Twenty-two patients were lost to follow-up, and attempts to ascertain their clinical status were unsuccessful. Vital status was assessed in all patients. The mean duration of follow-up was 10.5±3.0 years. Median follow-up was 11.3 years (95% confidence interval (CI) 8.2-14.3). The average age of the cohort was 53.3±7.7 years. The study assessed survival and all-cause mortality annually. Results: The frequency of chronic hepatitis B in the group of patients with active tuberculosis was 3.8%, hepatitis C - 14.8%, hepatitis B and C - 0.5% of cases. Such an incidence of viral hepatitis is associated with a high frequency of illicit drug users (62.4%). It should be noted that the frequency of hepatitis treatment was low and amounted to 8.7%. When assessing the contribution of hepatitis B and C to the mortality of patients with active tuberculosis, it was found that hepatitis is not a predictor of death in patients. At the same time, patients who did not receive hepatitis therapy had a higher risk of death (unadjusted odds ratio (OR) - 1.28, 95% CI 1.04-1.65). The adjusted OR for hepatitis B was - 1.87 95% CI 0.67-1.52, C - 1.24 95% CI 0.90-2.18, B and C - 1.72 95% CI 0.99-2.02. Conclusion: The presence of chronic viral hepatitis B and/or C in patients with active tuberculosis did not affect mortality from all causes and regardless of the type of virus during a long period of observation. Patients who did not receive treatment for viral hepatitis and who had a history of tuberculosis had a higher risk of death from all causes (OR 1.28, 95% CI 1.04-1.65).

show abstract

Reactivation of peritoneal and pleural tuberculosis during hepatitis C treatment with direct-acting antivirals

Cited by 3 publications

References 11 publications

Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study

Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study

Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study

The role of viral hepatitis B and C in the development of adverse outcomes in patients after tuberculosis

Contact Info

Product

Resources

About